Drug intelligence / Profile preview

C220

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Ophthalmic

Overview

C220 is a synthesized arylpiperazine derivative that was investigated for its effects on intraocular pressure (IOP). In an IOP recovery method using New Zealand rabbits, C220 demonstrated an IOP lowering effect, though it was less significant compared to other compounds like BG31 and YCT2-2. However, in an alpha-chymotrypsin-induced glaucoma model, C220 showed a trend to increase IOP over time. The compound was topically instilled onto the eyes in these animal models.

Beyond the preview

Go deeper on C220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C220.

Explore the full profile